TLR5-Derived, TIR-Interacting Decoy Peptides to Inhibit TLR Signaling
The Journal of Immunology · 2023
DOI: 10.4049/jimmunol.2200394 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2023. Verfasst von Artur Javmen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD. Hauptthemen laut MEDLINE: Toll-Like Receptor 5, Myeloid Differentiation Factor 88. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
TLR5, which is activated by flagellin, plays an important role in initiating immune response to a broad spectrum of motile bacterial pathogens. TLRs induce intracellular signaling via dimerization of their TIR domains followed by adapter recruitment through multiple interactions of receptor and adapter TIRs. Here, a library of cell-permeable decoy peptides derived from the TLR5 TIR was screened for TLR5 signaling inhibition in the HEK-Blue-mTLR5 reporter cell line. The peptide demonstrating the strongest inhibition, 5R667, corresponded to the second helix of the region between the third and fourth β-strands (helix C″). In addition to the TLR5-induced cytokine expression, 5R667 inhibited cytokine expression elicited by TLR4, TLR2, and TLR9. 5R667 also suppressed the systemic cytokine induction elicited by LPS administration in mice. 5R667 binding specificity was studied by time-resolved fluorescence spectroscopy in a cell-based assay. 5R667 demonstrated a multispecific binding pattern with respect to TIR domains: It bound TIRs of TLR adapters of the MyD88-dependent pathway, Toll/interleukin-1 receptor domain-containing adapter protein/MyD88 adapter-like (TIRAP) and MyD88, and also the TIR of TLR5. TR667, the peptide derived from the TIRAP region, which is structurally homologous to 5R667, demonstrated binding and inhibitory properties similar to that of 5R667. The surface-exposed residues within TIR regions represented by 5R667 and TR667 form motifs, which are nearly 90% conserved in vertebrate evolution and are distinctive of TLR5 and TIRAP TIR domains. Thus, we have identified an evolutionary conserved adapter recruitment motif within TLR5 TIR, the function of which can be inhibited by selective cell-permeable decoy peptides, which can serve as pan-specific TLR inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD.
- Institute for Biomedical Sciences, Georgia State University, Atlanta, GA.
- Center for Fluorescence Spectroscopy, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD.
ORCID-Profile: Shreeram C Nallar, Henryk Szmacinski, Andrew T Gewirtz, Vladimir Y Toshchakov
Förderung
- NIAID NIH HHS
- NIDDK NIH HHS
- NIGMS NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases
- HHS | NIH | National Institute of General Medical Sciences
Zitieren
APA
Javmen, A., Zou, J., Nallar, S. C., Szmacinski, H., Lakowicz, J. R., Gewirtz, A. T., & Toshchakov, V. Y. (2023). TLR5-Derived, TIR-Interacting Decoy Peptides to Inhibit TLR Signaling. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2200394
Vancouver
Javmen A, Zou J, Nallar SC, Szmacinski H, Lakowicz JR, Gewirtz AT, et al. TLR5-Derived, TIR-Interacting Decoy Peptides to Inhibit TLR Signaling. The Journal of Immunology. 2023. doi:10.4049/jimmunol.2200394
BibTeX
@article{Javmen2023,
author = {Javmen, Artur and Zou, Jun and Nallar, Shreeram C and Szmacinski, Henryk and Lakowicz, Joseph R and Gewirtz, Andrew T and Toshchakov, Vladimir Y},
title = {TLR5-Derived, TIR-Interacting Decoy Peptides to Inhibit TLR Signaling},
journal = {The Journal of Immunology},
year = {2023},
doi = {10.4049/jimmunol.2200394}
}
EUVIMED